- Home
- LESL vs FHTX Comparison
LESL vs FHTX Comparison
Compare LESL & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LESL
- FHTX
- Stock Information
- Founded
- LESL 1963
- FHTX 2015
- Country
- LESL United States
- FHTX United States
- Employees
- LESL N/A
- FHTX N/A
- Industry
- LESL Diversified Commercial Services
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- LESL Miscellaneous
- FHTX Health Care
- Exchange
- LESL Nasdaq
- FHTX Nasdaq
- Market Cap
- LESL 538.1M
- FHTX 513.7M
- IPO Year
- LESL 2020
- FHTX 2020
- Fundamental
- Price
- LESL $3.02
- FHTX $8.01
- Analyst Decision
- LESL Hold
- FHTX Strong Buy
- Analyst Count
- LESL 9
- FHTX 5
- Target Price
- LESL $4.38
- FHTX $16.00
- AVG Volume (30 Days)
- LESL 3.9M
- FHTX 134.3K
- Earning Date
- LESL 11-25-2024
- FHTX 11-04-2024
- Dividend Yield
- LESL N/A
- FHTX N/A
- EPS Growth
- LESL N/A
- FHTX N/A
- EPS
- LESL 0.02
- FHTX N/A
- Revenue
- LESL $1,364,632,000.00
- FHTX $25,515,000.00
- Revenue This Year
- LESL N/A
- FHTX N/A
- Revenue Next Year
- LESL $3.67
- FHTX $8.77
- P/E Ratio
- LESL $184.20
- FHTX N/A
- Revenue Growth
- LESL N/A
- FHTX N/A
- 52 Week Low
- LESL $2.42
- FHTX $2.70
- 52 Week High
- LESL $8.21
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- LESL 54.90
- FHTX 44.69
- Support Level
- LESL $2.73
- FHTX $8.52
- Resistance Level
- LESL $3.14
- FHTX $9.33
- Average True Range (ATR)
- LESL 0.20
- FHTX 0.70
- MACD
- LESL 0.00
- FHTX 0.00
- Stochastic Oscillator
- LESL 61.40
- FHTX 28.69
About LESL Leslie's Inc.
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products across chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company offers its products and services for Residential Pool, Residential Spa, Professional Pool, and Commercial Pool consumers. Geographically, it operates only in the United States.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.